Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Valencia, A, Masala, E, Rossi, A, Martino, A, Sanna, A, Buchi, F, Canzian, F, Cilloni, D, Gaidano, V, Voso, M T, Kosmider, O, Fontenay, M, Gozzini, A, Bosi, A, Santini, V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948159/
https://www.ncbi.nlm.nih.gov/pubmed/24192812
http://dx.doi.org/10.1038/leu.2013.330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948159/
https://www.ncbi.nlm.nih.gov/pubmed/24192812
http://dx.doi.org/10.1038/leu.2013.330

Ejemplares similares